Dapagliflozin ameliorates myocardial ischemia/reperfusion injury by modulating EGFR signaling and targeting NCOA4-mediated ferritinophagy
{{output}}
Background: SGLT2 inhibitor dapagliflozin (Dapa) has gained increasing attention in the treatment of myocardial ischemia-reperfusion injury (IRI). However, the mechanism of action of the cardiovascular benefits of Dapa is unclear... ...
